Home The Word Brain	My Amedeo FAQ Privacy About
	Hanzi Hunter — ultra-fast Hanzi study All 1,152 characters from the aioLingua manual Abstract • About • The 20 audio files ← aioLingua Chinese Online ← Chinese aioLingua PDF

Breast Cancer

Free Subscription 01.12.2025 10 Ann Surg Oncol 16 BMC Cancer 1 BMJ 1 Br J Cancer 2 Breast Cancer 1 Breast Cancer (Auckl) 6 Breast Cancer Res 11 Breast Cancer Res Treat 1 Breast J 5 Clin Breast Cancer 2 Eur J Cancer 4 Eur J Surg Oncol 2 Int J Oncol 3 Int J Radiat Oncol Biol Phys 1 J Biol Chem 1 J Clin Invest 1 J Clin Oncol 1 J Natl Cancer Inst 2 J Surg Oncol 5 Lancet Oncol 1 Mod Pathol 6 NPJ Breast Cancer 1 Oncogene 4 PLoS One 1 Radiology

Retrieve available abstracts of this week’s articles: HTML format

Single Articles

Ann Surg Oncol

1. TSUCHIDA J, Wu R, Nagahashi M, Ebos JML, et al
   TRIM37 Expression is Associated with Immune Suppression Poor Response to Neoadjuvant Chemotherapy and Worse Survival in ER-Positive/HER2-Negative Breast Cancer.
   Ann Surg Oncol. 2025 Nov 21. doi: 10.1245/s10434-025-18764.
   PubMed         Abstract available
   
   
2. COBB AN, Cortina CS
   Reply to: Letter to the Editor of Annals of Surgical Oncology Concerning "Evaluating Survival and Treatment Patterns Using the National Cancer Database in HER2-Positive Breast Cancer," by Sanli, Deniz et al.
   Ann Surg Oncol. 2025 Nov 22. doi: 10.1245/s10434-025-18797.
   PubMed        
   
   
3. RANGEL M, Paul S, Gupta D, McPeek C, et al
   ASO Visual Abstract: Evaluating the Gail Model: Racial Disparities in Breast Cancer Risk Assessment.
   Ann Surg Oncol. 2025 Nov 23. doi: 10.1245/s10434-025-18753.
   PubMed        
   
   
4. WAGNER BD, Rubin J, Lin IH, Raina J, et al
   ASO Visual Abstract: Clinical Features, Microbial Epidemiology, and Recurrence Risk of Cellulitis in Breast Cancer-Related Lymphedema.
   Ann Surg Oncol. 2025 Nov 23. doi: 10.1245/s10434-025-18789.
   PubMed        
   
   
5. WANG T, Neish D, Thomas S, Botty van den Bruele A, et al
   Radiation De-Escalation in Older Women with Early-Stage ER+/HER2- Invasive Breast Cancer.
   Ann Surg Oncol. 2025 Nov 23. doi: 10.1245/s10434-025-18746.
   PubMed         Abstract available
   
   
6. ROSS VMS, Addie M, Roy Pickard M, Josey V, et al
   Axillary Management in Breast Cancer Patients with Positive Lymph Nodes Following Neoadjuvant Chemotherapy.
   Ann Surg Oncol. 2025 Nov 26. doi: 10.1245/s10434-025-18783.
   PubMed         Abstract available
   
   
7. COBB AN, Dong X, Makope A, Cohen L, et al
   Correction: Contemporary Nodal Management and Overall Survival of Older Patients with HR-/HER2+ Breast Cancer.
   Ann Surg Oncol. 2025 Nov 25. doi: 10.1245/s10434-025-18811.
   PubMed        
   
   
8. GHOSH M, Hoysal DR, Deshpande A, Badwe RA, et al
   Letter to the Editor "Impact of Time to Surgery Post Neoadjuvant Chemotherapy on Breast Cancer Outcomes: A Retrospective Study of Patients Enrolled in the I-SPY 2 Clinical Trial".
   Ann Surg Oncol. 2025 Nov 25. doi: 10.1245/s10434-025-18788.
   PubMed        
   
   
9. SHEN Y, Gadiraju GK, Gao R, Nakhlis Md F, et al
   ASO Author Reflections: Beyond Survival: Restoring Quality of Life in Inflammatory Breast Cancer.
   Ann Surg Oncol. 2025 Nov 24. doi: 10.1245/s10434-025-18700.
   PubMed        
   
   
10. TEKCAN SANLI DE, Sanli AN
    Evaluating Survival and Treatment Patterns Using the National Cancer Database in HER2-Positive Breast Cancer.
    Ann Surg Oncol. 2025 Nov 24. doi: 10.1245/s10434-025-18796.
    PubMed        
    
    

    
    BMC Cancer

11. SALARI Z, Khosravi A, Riahi A, Molaakbari E, et al
    Niosomal mefloquine and cisplatin in breast cancer: comparative effects on apoptosis and angiogenesis via in vitro and in silico analysis.
    BMC Cancer. 2025 Nov 26. doi: 10.1186/s12885-025-15372.
    PubMed         Abstract available
    
    
12. MALAWARAARACHCHI BP, Abeysinghe C, Seneviwickrama M, Ranasinghe S, et al
    Body image concerns among women diagnosed with breast cancer in a South Asian setting: a phenomenology approach.
    BMC Cancer. 2025;25:1819.
    PubMed         Abstract available
    
    
13. OJEDELE OA, Hamdi N, Mughram MHA, Alyami EM, et al
    Identification of potential novel aromatase inhibitors as therapeutic strategies against breast cancer: insight into molecular docking, MD simulations and ADMET profiling.
    BMC Cancer. 2025;25:1812.
    PubMed         Abstract available
    
    
14. ZHANG H, Yin X, Wang S, Li Q, et al
    Combined elevation of myeloid-derived suppressor cells and Tregs predicts lymph node metastasis in breast cancer.
    BMC Cancer. 2025;25:1806.
    PubMed         Abstract available
    
    
15. DELABY C, Al Herk A, Hirtz C, Jacot W, et al
    Hepcidin as an emerging predictor biomarker of leptomeningeal metastases in patients with metastatic breast cancer.
    BMC Cancer. 2025;25:1801.
    PubMed         Abstract available
    
    
16. SHAWANA S, Mirza T, Khatoon A, Mushtaq S, et al
    Uncovering rare somatic variants in olfactory receptor genes in Pakistani triple-negative breast cancer patients.
    BMC Cancer. 2025;25:1799.
    PubMed         Abstract available
    
    
17. WANG A, Zeng P, Ma T, Shi H, et al
    Establishment of a new method for detection of TROP2-positive circulating tumor cells in breast cancer.
    BMC Cancer. 2025;25:1797.
    PubMed         Abstract available
    
    
18. YAN X, Zhang X, Wang Z, Yang L, et al
    Safety and efficacy of immune checkpoint inhibitors in patients with triple-negative breast cancer: a systematic review and meta-analysis.
    BMC Cancer. 2025;25:1804.
    PubMed         Abstract available
    
    
19. YU S, Wu J
    CTHRC1-driven breast cancer progression: insights from palmitoylation networks and spatial heterogeneity.
    BMC Cancer. 2025;25:1795.
    PubMed         Abstract available
    
    
20. YUAN S, Li J, Liu W, Ren M, et al
    CLIC3 emerges as a novel prognostic biomarker and therapeutic target in triple-negative breast cancer through integrated multi-omics analysis.
    BMC Cancer. 2025;25:1828.
    PubMed         Abstract available
    
    
21. DENG Z, Li Y, Luo Y, Cao X, et al
    Nomogram models for prediction of axillary lymph node metastasis in breast cancer patients.
    BMC Cancer. 2025;25:1827.
    PubMed         Abstract available
    
    
22. COELHO LL, Vianna MM, da Silva DM, Gonzaga BMS, et al
    beta-lapachone impairs viability, migration, and epithelial-mesenchymal transition in mammary tumor spheroids.
    BMC Cancer. 2025;25:1826.
    PubMed         Abstract available
    
    
23. SPERLICH S, Geyer S, Holthausen-Markou S, Park-Simon TW, et al
    Breast cancer survivors' participation in social activities five years after primary surgery - are there social inequalities?
    BMC Cancer. 2025;25:1829.
    PubMed         Abstract available
    
    
24. PINCHAS-MIZRACHI R, Bouhnik D
    Correction: The parity paradox: does number of children (parity) influence breast cancer mortality across the life course?
    BMC Cancer. 2025;25:1830.
    PubMed        
    
    
25. LI J, Liu J, Cai B, Yang C, et al
    Association of estimated glucose disposal rate with all-cause and breast cancer-specific mortality in US breast cancer survivors: a population-based study.
    BMC Cancer. 2025 Nov 27. doi: 10.1186/s12885-025-15340.
    PubMed         Abstract available
    
    
26. MARICIC VRBAN M, Radovani Trbojevic B, Visentin D, Ramljak K, et al
    Therapy-induced remodeling of IgG and plasma N-glycans in breast cancer.
    BMC Cancer. 2025 Nov 27. doi: 10.1186/s12885-025-15381.
    PubMed         Abstract available
    
    

    
    BMJ

27. 
    EXPRESSION OF CONCERN: First mammography screening participation and breast cancer incidence and mortality in the subsequent 25 years: population based cohort study.
    BMJ. 2025;391:r2394.
    PubMed        
    
    

    
    Br J Cancer

28. OH H, Yaghjyan L, Heng YJ, Baker GM, et al
    Birthweight, height, and body mass index in relation to the expression of stem cell markers among women with benign breast biopsies in the Nurses' Health Study II.
    Br J Cancer. 2025;133:1695-1707.
    PubMed         Abstract available
    
    

    
    Breast Cancer

29. REVELOU MT, Filippatos C, Malandrakis P, Terpos E, et al
    Antipsychotic therapy and breast cancer risk: a comprehensive systematic review and meta-analysis.
    Breast Cancer. 2025 Nov 27. doi: 10.1007/s12282-025-01804.
    PubMed         Abstract available
    
    
30. OGITA M, Sawayanagi S, Jinnouchi H, Yoshimura M, et al
    Postmastectomy radiation therapy for autologous breast reconstruction: a systematic review and meta-analysis for the 2022 Japanese Breast Cancer Society Clinical Practice Guideline.
    Breast Cancer. 2025 Nov 28. doi: 10.1007/s12282-025-01806.
    PubMed         Abstract available
    
    

    
    Breast Cancer (Auckl)

31. DATTA A, Mohammad SB, Bhowmik KK, Barek MA, et al
    MMP2 rs243865 and MMP8 rs11225395 Gene Polymorphisms Are Correlated With Breast Cancer Risk in Bangladeshi Women: Evidence From a Case-Control Study.
    Breast Cancer (Auckl). 2025;19:11782234251392714.
    PubMed         Abstract available
    
    

    
    Breast Cancer Res

32. MARIAPUN S, Eriksson M, Tai MC, Mohd Taib NA, et al
    Genome-wide association study of Asian women identifies putative mammographic density-associated loci.
    Breast Cancer Res. 2025;27:207.
    PubMed         Abstract available
    
    
33. LEE J, Park EY, Lee WJ
    Cardiovascular disease risk following radiotherapy among breast cancer survivors: a nationwide cohort study in South Korea.
    Breast Cancer Res. 2025 Nov 23. doi: 10.1186/s13058-025-02178.
    PubMed         Abstract available
    
    
34. LI S, Jiang QL, Gong HZ, Zeng Y, et al
    Autoimmune thyroiditis promotes breast cancer progression: exploratory role of thyroid hormone receptor beta signaling disruption.
    Breast Cancer Res. 2025 Nov 24. doi: 10.1186/s13058-025-02184.
    PubMed        
    
    
35. XU NN, Barnard ME, Holder EX, Rosenberg L, et al
    Perceived racial discrimination in health care in relation to late stage at breast cancer diagnosis.
    Breast Cancer Res. 2025;27:208.
    PubMed         Abstract available
    
    
36. XIA X, He X, Tang M, Chen Y, et al
    CAND1 mediates CUL7-dependent HER2 protein stability to drive breast cancer progression.
    Breast Cancer Res. 2025;27:211.
    PubMed         Abstract available
    
    
37. DONG H, Zhou M, Sun Q, Ren Y, et al
    Macrophages in obesity-related breast cancer: mechanistic insights and therapeutic opportunities.
    Breast Cancer Res. 2025;27:210.
    PubMed        
    
    

    
    Breast Cancer Res Treat

38. ZELIZER S, Gallagher GB, Gonen M, Dang C, et al
    Evaluating post-T-DXd treatment strategies in HER2-positive metastatic breast cancer.
    Breast Cancer Res Treat. 2025;215:19.
    PubMed         Abstract available
    
    
39. KAUR M, Quirarte A, Vertido A, Torosian T, et al
    Impact of concurrent lobular carcinoma in situ on recurrence outcomes in patients with classic and pleomorphic invasive lobular carcinoma of the breast.
    Breast Cancer Res Treat. 2025;215:20.
    PubMed         Abstract available
    
    
40. GHASEMI F, Arima J, Takabe K
    High PARP1 expression is associated with proliferative tumor biology in breast cancer.
    Breast Cancer Res Treat. 2025;215:21.
    PubMed         Abstract available
    
    
41. REAM M, Taub CJ, Rosenbaum AR, Olguin EO, et al
    Promoting Resilience in Stress Management (PRISM) for women with breast cancer: a qualitative analysis of patient impressions and recommendations.
    Breast Cancer Res Treat. 2025;215:22.
    PubMed         Abstract available
    
    
42. BERNIK S, Balija TM, Kim D, Cuadros A, et al
    Breast cancer patients treated at a New York City academic health system during the COVID-19 pandemic in 2021 had delayed presentations and more advanced disease than pre-pandemic cases.
    Breast Cancer Res Treat. 2025;215:23.
    PubMed         Abstract available
    
    
43. DOLEVICZENYI L, Frivaldszky L, Rancz A, Fedorcsak DL, et al
    The significance of perioperative glucocorticoids in the prevention of seroma formation after mastectomies: a systematic review and meta-analysis.
    Breast Cancer Res Treat. 2025;215:13.
    PubMed         Abstract available
    
    
44. MALHOTRA S, Choi DX, Sevilimedu V, Greenup RA, et al
    Association between hospital volume and survival in patients with locally advanced breast cancer.
    Breast Cancer Res Treat. 2025;215:15.
    PubMed         Abstract available
    
    
45. ZHAO Z, Lei H, Wang B, Guo L, et al
    Mesothelin-expressing triple-negative breast cancer: a highly invasive and immunosuppressive subtype.
    Breast Cancer Res Treat. 2025;215:18.
    PubMed         Abstract available
    
    
46. ABABNEH HS, Naoum GE, Niemierko A, Ly A, et al
    Analysis of factors associated with loco-regional failure in breast cancer patients following neoadjuvant chemotherapy.
    Breast Cancer Res Treat. 2025;215:17.
    PubMed         Abstract available
    
    
47. CANDELL L, Foulad D, Wapnir I, Tsai J, et al
    Breast cancer diagnosis at age 85 and older.
    Breast Cancer Res Treat. 2025;215:14.
    PubMed         Abstract available
    
    
48. IWAI C, Konishi T, Miyawaki A, Okada A, et al
    Cardiovascular adverse events associated with denosumab versus zoledronic acid in patients with breast cancer: a propensity score overlap weighted analysis.
    Breast Cancer Res Treat. 2025;215:16.
    PubMed         Abstract available
    
    

    
    Breast J

49. MORANTE Z, Ferreyra Y, Otoya I, Valdiviezo N, et al
    Influence of HER2 Changes on Survival Outcomes After Neoadjuvant Chemotherapy in Peruvian Patients With Triple-Negative Breast Cancer.
    Breast J. 2025;2025:3770655.
    PubMed         Abstract available
    
    

    
    Clin Breast Cancer

50. YE L, Dai Y, Chen L, Liang Y, et al
    Effect of HER2-Low Expression on the Efficacy of CDK4/6 Inhibitors in Breast Cancer: A Meta-Analysis.
    Clin Breast Cancer. 2025 Oct 30:S1526-8209(25)00308.
    PubMed         Abstract available
    
    
51. KNOEDLER S, Diatta F, Hu K, Klimitz F, et al
    Prevention's Price-30-Day Outcomes of Risk-Reducing Mastectomy and Immediate Free Flap Breast Reconstruction.
    Clin Breast Cancer. 2025;25:e1122-e1128.
    PubMed         Abstract available
    
    
52. HUYNH Y, Mann GB, Nickson C, Rose AK, et al
    Relationship Between Patient Age, Mammographic Density and Background Parenchymal Enhancement on Contrast-Enhanced Mammography.
    Clin Breast Cancer. 2025;25:e1066-e1073.
    PubMed         Abstract available
    
    
53. AO Y, Li X, Mu L, Zhao J, et al
    Time-Dependent Apparent Diffusion Coefficient Changes in Breast MR Images With Contrast for Tumor Characterization.
    Clin Breast Cancer. 2025;25:817-825.
    PubMed         Abstract available
    
    
54. ANTONINI M, Mattar A, Facina G, Cavalcante FP, et al
    Immunohistochemical Changes After Neoadjuvant Chemotherapy and Their Impact on Breast Cancer Survival: A Systematic Review and Meta-analysis.
    Clin Breast Cancer. 2025 Nov 1:S1526-8209(25)00307.
    PubMed         Abstract available
    
    

    
    Eur J Cancer

55. NICOLO E, Reduzzi C, Pierga JY, Gazzaniga P, et al
    International expert consensus on the clinical integration of circulating tumor cells in solid tumors.
    Eur J Cancer. 2025;231:116050.
    PubMed         Abstract available
    
    
56. ZUO H, Vaihenberg E, Singh A, Bal G, et al
    Response to letter Re: Impact of early discontinuation of adjuvant endocrine therapy on survival in breast cancer: A target trial emulation.
    Eur J Cancer. 2025;232:116113.
    PubMed        
    
    

    
    Eur J Surg Oncol

57. WANG S, Zhang H, Lin J, Meng H, et al
    Clinical efficacy and psychological benefits of ultrasound-guided vacuum-assisted excision in outpatient management of benign breast lesions.
    Eur J Surg Oncol. 2025;51:110498.
    PubMed         Abstract available
    
    
58. PISARCIK D, Heimer J, Farkas M, Kubik-Huch RA, et al
    Qualitative and quantitative analysis of stereotactic-guided positioning of the Pintuition marker in pre-surgical localization of non-palpable breast lesions.
    Eur J Surg Oncol. 2025;51:110495.
    PubMed         Abstract available
    
    
59. SCHOENEN S, Martinez Gomez C, Pasquesoone C, Alline J, et al
    Evaluation of risk-reducing radical fimbriectomy followed by delayed oophorectomy in high-risk Women: A single-center retrospective study.
    Eur J Surg Oncol. 2025;51:110469.
    PubMed         Abstract available
    
    
60. MOUAWAD J, French J, Meybodi F, Stuart K, et al
    Breast sensation following nipple-sparing mastectomy versus breast-conserving surgery: a mixed-methods study.
    Eur J Surg Oncol. 2025;51:110477.
    PubMed         Abstract available
    
    

    
    Int J Oncol

61. LI F, Gao Z
    Obesity, chronic breast inflammation and carcinogenesis: Molecular pathways and clinical implications (Review).
    Int J Oncol. 2026;68:12.
    PubMed         Abstract available
    
    
62. LUO J, Yang Y, Cheng L, Cheng F, et al
    Discovery of the late autophagy inhibitor FZU?0045?053 and its anti?breast cancer and immunomodulatory effects.
    Int J Oncol. 2026;68:10.
    PubMed         Abstract available
    
    

    
    Int J Radiat Oncol Biol Phys

63. NANGIA S
    Calculation of the absolute risk of a radiation-induced acute coronary event in breast cancer patients: a hypothesis incorporating Indian ethnicity.
    Int J Radiat Oncol Biol Phys. 2025 Nov 20:S0360-3016(25)06479.
    PubMed         Abstract available
    
    
64. HYUCK JEON S, Park N, Kim Y, Kim JH, et al
    Radiotherapy increases circulating early-stage natural killer cells with enhanced cytokine responsiveness in breast cancer.
    Int J Radiat Oncol Biol Phys. 2025 Nov 20:S0360-3016(25)06486.
    PubMed         Abstract available
    
    
65. UNTERKIRHERS S, Erni S, Gruber G, Schneider U, et al
    Poisson LQ TCP Model Validation in Micro- and Macroscopic Breast-Cancer Radiotherapy.
    Int J Radiat Oncol Biol Phys. 2025 Nov 23:S0360-3016(25)06482.
    PubMed         Abstract available
    
    

    
    J Biol Chem

66. SARKAR S, Chatterjee A, Paul S, Bisoi A, et al
    G-Quadruplex-specific action of chloroquine-based immunomodulator drugs to inhibit the cancer progression.
    J Biol Chem. 2025;301:110753.
    PubMed         Abstract available
    
    

    
    J Clin Invest

67. PALOMEQUE JA, Serra-Mir G, Blasco-Benito S, Brunel H, et al
    Estrogen Receptor signaling drives immune evasion and immunotherapy resistance in HR+ breast cancer.
    J Clin Invest. 2025 Nov 25:e193153. doi: 10.1172/JCI193153.
    PubMed         Abstract available
    
    

    
    J Clin Oncol

68. LI JJ, Zhang WJ, Zeng XH, Zhang QY, et al
    Efficacy and Safety of Neoadjuvant TQB2102 in Locally Advanced or Early Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: A Randomized, Open-Label, Multicenter, Phase II Trial.
    J Clin Oncol. 2025 Nov 25:JCO2501153. doi: 10.1200/JCO-25-01153.
    PubMed         Abstract available
    
    

    
    J Natl Cancer Inst

69. CHOI E, Zhai W, Ahn J, Ahles TA, et al
    Neighborhood deprivation on increasing deficit accumulation in older breast cancer survivors and non-cancer controls.
    J Natl Cancer Inst. 2025 Nov 22:djaf337. doi: 10.1093.
    PubMed         Abstract available
    
    

    
    J Surg Oncol

70. DE LA CRUZ KU G, Desai A, Ho I, King C, et al
    Post-Operative Outcomes Across the Levels of Oncoplastic Breast Surgery According to the American Society of Breast Surgeons Oncoplastic Surgery Definition and Classification System.
    J Surg Oncol. 2025;132:1307-1316.
    PubMed         Abstract available
    
    
71. ALBUAINAIN RY, Althawadi R, Eid R, Abdulla HA, et al
    Oncological Outcomes of Omitting Axillary Surgery in Early Breast Cancer: A Systematic Review and Meta-Analysis.
    J Surg Oncol. 2025 Nov 26. doi: 10.1002/jso.70145.
    PubMed         Abstract available
    
    

    
    Lancet Oncol

72. PFOB A, Pinker K, Vaz-Luis I, Di Meglio A, et al
    The Lucerne Toolbox 3: digital health and artificial intelligence to optimise the patient journey in early breast cancer-a multidisciplinary consensus.
    Lancet Oncol. 2025;26:e694-e706.
    PubMed         Abstract available
    
    
73. CONFORTI F, Holtschmidt J, Nekljudova V, Sala I, et al
    Distant disease-free survival as a surrogate endpoint for overall survival in randomised trials of neoadjuvant therapy for early breast cancer: a pooled analysis of GBG and AGO-B Study Group trials.
    Lancet Oncol. 2025;26:1584-1597.
    PubMed         Abstract available
    
    
74. YUAN J, Bi XW, Hua X, Huang H, et al
    Metronomic capecitabine as extended adjuvant chemotherapy for early triple-negative breast cancer (SYSUCC-001): updated 10-year outcomes and post-hoc exploratory biomarker analysis from a randomised, phase 3 trial.
    Lancet Oncol. 2025;26:1575-1583.
    PubMed         Abstract available
    
    
75. LI H, Liu J, Ouyang Q, Wang S, et al
    Fuzuloparib with or without apatinib in patients with HER2-negative metastatic breast cancer with germline BRCA1/2 mutations (FABULOUS): interim analysis of a multicentre, three-arm, open-label, randomised, phase 3 trial.
    Lancet Oncol. 2025;26:1563-1574.
    PubMed         Abstract available
    
    
76. SIKOV WM
    Adjuvant capecitabine in early-stage triple-negative breast cancer? Yes, but for whom?
    Lancet Oncol. 2025;26:1515-1517.
    PubMed        
    
    

    
    Mod Pathol

77. LU X, Luo B, Wei Y, Bu H, et al
    Histologic Categorization of Desmoplastic Reaction in Triple-Negative Breast Cancer: Its Relevance to Neoadjuvant Chemoimmunotherapy Response and Tumor Biology.
    Mod Pathol. 2025 Nov 26:100943. doi: 10.1016/j.modpat.2025.100943.
    PubMed         Abstract available
    
    

    
    NPJ Breast Cancer

78. CHISLOCK EM, Pan TC, Pant D, Chen Y, et al
    DTC-Flow: a flow cytometry-based detection platform for characterizing bone marrow disseminated tumor cells in breast cancer.
    NPJ Breast Cancer. 2025 Nov 24. doi: 10.1038/s41523-025-00853.
    PubMed         Abstract available
    
    
79. OH JH, Ahn S, Jang M, Yoon Y, et al
    Nomogram for predicting axillary pathologic complete response in cN2-3 breast cancer after neoadjuvant chemotherapy.
    NPJ Breast Cancer. 2025 Nov 24. doi: 10.1038/s41523-025-00862.
    PubMed         Abstract available
    
    
80. HUNDAL J, Ashruf OS, Li H, Basen-Engquist K, et al
    Racial and demographic disparities in glp-1ra use among breast cancer patients with Type 2 Diabetes.
    NPJ Breast Cancer. 2025;11:131.
    PubMed         Abstract available
    
    
81. BONOMI G, Griguolo G, Giarratano T, Zanghi F, et al
    Real-world outcomes of early-stage HER2-positive breast cancer patients treated with adjuvant paclitaxel and trastuzumab.
    NPJ Breast Cancer. 2025;11:132.
    PubMed         Abstract available
    
    
82. HARRIS AE, Lothion-Roy J, Thompson RL, Haque M, et al
    Functional and clinical significance of the RNA m(6)A methyltransferase complex in breast cancer.
    NPJ Breast Cancer. 2025 Nov 27. doi: 10.1038/s41523-025-00861.
    PubMed         Abstract available
    
    
83. YAZAKI S, Kitadai R, Momozawa Y, Yoshida T, et al
    Germline variants of the POLH and RAD51 genes are candidate variants associated with risk of hormone receptor-negative young-onset breast cancer.
    NPJ Breast Cancer. 2025;11:133.
    PubMed         Abstract available
    
    

    
    Oncogene

84. LI M, Xie W, Hu K, Li T, et al
    The novel endogenous micropeptide XLH-36 binds Gemin4 to promote triple-negative breast cancer metastasis.
    Oncogene. 2025 Nov 29. doi: 10.1038/s41388-025-03621.
    PubMed         Abstract available
    
    

    
    PLoS One

85. STUTZIN DONOSO F, Archer S, Walter FM, Morris S, et al
    CanRisk-GP protocol: A feasibility study of incorporating proactive multifactorial breast cancer risk assessment into general practice.
    PLoS One. 2025;20:e0336902.
    PubMed         Abstract available
    
    
86. AL DHAHERI Y, Attoub S, Ramadan G, Arafat K, et al
    Correction: Carnosol Induces ROS-Mediated Beclin1-Independent Autophagy and Apoptosis in Triple Negative Breast Cancer.
    PLoS One. 2025;20:e0337572.
    PubMed         Abstract available
    
    
87. VAN CAPPELLEN-VAN MALDEGEM SJM, Kruif A, Seidell JC, van de Poll-Franse LV, et al
    Determinants and timing of lifestyle changes in postmenopausal breast cancer survivors: A longitudinal qualitative study.
    PLoS One. 2025;20:e0337089.
    PubMed         Abstract available
    
    
88. LI W, Wang X, Yu Q, Zhou W, et al
    Symptom network analysis in breast cancer patients: A scoping review.
    PLoS One. 2025;20:e0336793.
    PubMed         Abstract available
    
    

    
    Radiology

89. YAO MM, Vy VPT, Lee CS, Chang YC, et al
    Identification of Risk Factors for Interval Breast Cancer in a Population-based Screening Program.
    Radiology. 2025;317:e243918.
    PubMed         Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Breast Cancer is free of charge.